Sagimet's fatty liver disease drug shows promise in trial
22/01/2024 12:11
Jan 22 (Reuters) - Sagimet Biosciences SGMT.O said on Monday its experimental drug was statistically significant in reducing symptoms of a fatty liver disease in a mid-stage study. (Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage